and can convert established rat cell 3 Corresponding author lines to tumorigenicity (Small et al., 1987) . Transgenic mice that overexpress MYCN under control of the immunoThe proto-oncogene MYCN is often amplified in human globulin heavy chain enhancer develop lymphoid tumors neuroblastomas. The assumption that the amplification (Dildrop et al., 1989; Rosenbaum et al., 1989) . These data contributes to tumorigenesis has never been tested suggest that MYCN has a role in modulating cellular directly. We have created transgenic mice that overproliferation, but the evidence that MYCN actually conexpress MYCN in neuroectodermal cells and develop tributes to neuroblast transformation remains inferential.
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neuroblastoma. Analysis of tumors by comparative
In an effort to explore the role of MYCN in neurogenomic hybridization revealed gains and losses of at blastoma, we created transgenic mice that overexpress least seven chromosomal regions, all of which are MYCN in cells derived from the neural crest. Such syntenic with comparable abnormalities detected in animals develop neuroblastoma several months after birth, human neuroblastomas. In addition, we have shown demonstrating that overexpression of MYCN can initiate that increases in MYCN dosage or deficiencies in either tumorigenesis. The latent period prior to neuroblastoma of the tumor suppressor genes NF1 or RB1 can augment development suggests that additional genetic events contumorigenesis by the transgene. Our results provide tribute to tumor formation. By comparative genomic direct evidence that MYCN can contribute to the genesis hybridization (CGH), neuroblastomas from the transgenic of neuroblastoma, suggest that the genetic events mice demonstrate a number of consistent chromosomal involved in the genesis of neuroblastoma can be tumorigains and losses in regions syntenic with those observed genic in more than one chronological sequence, and in human neuroblastoma. These mice represent a model offer a model for further study of the pathogenesis for neuroblastoma that may be useful both to identify and therapy of neuroblastoma.
additional genes involved in tumorigenesis, and to test Keywords: comparative genomic hybridization/MYCN/ new therapies in preclinical trials. neuroblastoma/N-myc /transgenic
Results

Targeting MYCN overexpression to the neural
Introduction crest
During development, neuroblasts appear as a normal Neuroblastoma is a tumor of neural crest origin that constituent of the neural crest. To target expression of comprises 8-10% of all childhood malignancies and causes human MYCN to these cells, we used the tyrosine 15% of cancer-related deaths in children. Ninety percent hydroxylase promotor (Figure 1 ). This promotor is active of cases strike children Ͻ10 years old (Matthay, 1995) .
in migrating cells of the neural crest early in development The tumor arises anywhere in the sympathetic nervous (Banerjee et al., 1992) , and has been shown to direct system, most frequently in the adrenal medulla and in expression of chloramphenicol acetyl transferase to symparaspinal ganglia (Brodeur and Castleberry, 1993) . The pathetic ganglia and the adrenal, in which neuroblastomas best characterized genetic abnormality in neuroblastoma often arise (Banerjee et al., 1992) . As hoped, mice carrying is amplification of MYCN, a gene originally isolated from the transgenic construct showed tissue-specific expression neuroblastoma cells (Kohl et al., 1983; of the MYCN protein product (Mycn). By Western analysis, 1983). Amplification of MYCN occurs in approximately
Mycn was expressed at high levels in the adrenal gland, one-third of neuroblastomas and correlates with advanced which is derived from the neural crest ( Figure 2a ). There disease, suggesting that amplification of MYCN is a late was marginal expression in brain, heart, testes and spleen event in tumorigenesis (Brodeur et al., 1984; Kohl et al., (data not shown). 1984 ). An alternative interpretation of these data is that MYCN-dependent and MYCN-independent pathways exist Neuroblastomas in mice overexpressing the MYCN early in neuronal transformation, and that the MYCNtransgene dependent transformation leads to more aggressive tumors Three independent MYCN transgenic lines developed thoracic paraspinous masses (Table I ). The histology of with a worse prognosis. In either event, it is not known Fig. 1 . Construct used for generating tissue-specific expression of the MYCN transgene. A cDNA for human MYCN was ligated downstream of the rat tyrosine hydroxylase promotor. The rabbit β-globin enhancer was used to enhance expression, and a herpes simplex virus thymidine kinase gene sequence was used as a transcription terminator. The transgene was cleaved from vector sequences using NsiI. E, EcoRI; S, SalI; N, NsiI.
these tumors was consistent with neuroblastoma. Tumors showed varying degrees of neuronal differentiation, as found in regions where ganglia are not known to reside; Lu, lung; M, muscle; Sk, skin; Sp, spleen; T, testes. The positive control was from Kelly cells (Schwab et al., 1983) Tumors stained positively for the neuronal markers Hemizygous and homozygous refer to mice with one or two alleles of synaptophysin and neuron-specific enolase (Figure 3c the MYCN transgene insertion. and d). Tumor cells with ganglionic differentiation were positive for the marker S100 (Nakagawara et al., 1986) , while anaplastic tumor cells remained negative. Tumor cells did not react with antibodies for chromogranin A which has high levels of MYCN amplification (Schwab et al., 1983 were followed for tumor development. glands, kidney, intestine and other organs. Six animals abdominal masses appeared otherwise normal. offspring from the above cross were interbred and 13 offspring homozygous for the MYCN transgene were followed (u). (b) Survival of MYCN transgenic mice carrying hemizygous inactivating mutations in p53, NF1 and RB1. The outbred founder line was back-crossed once to C57BL6/J, and then to a p53ϩ/-mouse in an FVB/N strain deletions of RB1 or NF1, but not carrying the MYCN background. Twenty three mice hemizygous for the MYCN transgene transgene. These data suggest that loss of either NF1 or and heterozygous for the p53 inactivating mutation were followed (d).
RB1 can contribute to tumorigenesis in mice overexpressTwenty seven littermates transgenic for MYCN but wild-type at p53 ing MYCN.
were followed to control fo strain effects (n). The outbred founder line was back-crossed once to C57BL6/J, then crossed to a 129S/v Structural mutations in p53 are rare in human neuromouse heterozygous for NF1 or RB1 inactivating mutations. Fifteen blastoma (Imamura et al., 1993; Hosoi et al., 1994) . To transgene and heterozygous for deletion of p53 showed a tumor incidence similar to that of littermates hemizygous for the MYCN transgene and wild-type at the p53 locus Tumor formation is dependent on MYCN gene dosage ( Figure 4b ). The tumor penetrance in mice hemizygous for the MYCN transgene and wild-type at the p53 locus To determine whether transgene dosage is related to tumor incidence, transgenic mice were crossed to produce was less than that seen in similar mice back-crossed to a C57BL6/J background (Figure 4 ), even though these mice homozygosity for the MYCN transgene. Homozygotes displayed both increased incidence and decreased latency were back-crossed to FVB/N only once. MYCN transgenic mice lacking both p53 alleles were also generated, and of tumor formation, approaching 100% at 4 months ( Figure 4a ).
did not show increased tumor penetrance (data not shown). To test whether γ irradiation could increase tumor penetrance, mice hemizygous for the MYCN transgene were irradiated at 3-4 Gy before day 3 of life. No increase Analysis of tumors by comparative genomic hybridization in tumor incidence was seen in these animals.
To examine genetic aberrations at the chromosomal level, we used CGH to analyze 21 tumors from hemizygous and Additional genetic lesions contribute to tumorigenesis homozygous mice. This technique is based on two-color fluorescence in situ hybridization and scans the entire genIn the limited studies performed to date, loss of NF1 occurs commonly, and loss of RB1 rarely in human ome for gains and losses of chromosomal material. Tumors from five homozygous mice and three hemizygous mouse neuroblastoma cell lines or tumor tissue (Nakamura et al., 1991; Johnson et al., 1993; The et al., 1993) . To test showed no chromosomal changes. Thirteen tumors (all from hemizygous mice) showed gains and losses of chromosomal whether loss of these tumor suppressor genes could increase tumor penetrance, mice lacking NF1 and RB1 regions ( Figure 8 , Table II ). In mice hemizygous for the MYCN transgene, chromosomal regions were most comwere crossed to mice that overexpressed MYCN. Mice homozygous for NF1 and RB1 deletions die at midgestation monly gained on chromosomes 11 (5/16) and 17 (6/16). These regions are syntenic with human chromosomes 6 (Jacks et al., 1992 (Jacks et al., , 1994 . In order to avoid this complication, mice were generated that were hemizygous for the and 17 respectively (Copeland et al., 1993) , both of which commonly are gained in human neuroblastoma (Plantaz MYCN transgene and heterozygous for deletions of NF1 or RB1. Such mice had a decreased latency, and an et al., 1997). Chromosomal loss was most often detected on chromosomes 5 (4/16), 9 (3/16), 16 (4/16) and X (4/16). increased incidence of tumors, to~75% by 10 months (Figure 4b ). The NF1 and RB1 mutant mice were in a These chromosomes are syntenic with human chromosomes 4, 11, 3 and X respectively (Copeland et al., 1993) , all of 129S/v strain background, so littermates wild-type at the tumor suppressor loci and carrying the MYCN transgene which commonly are lost in human neuroblastoma (Plantaz et al., 1997) . were also followed to control for strain effects. Littermates had a tumor penetrance of 40% at 10 months (Figure 4b) .
Gain of chromosome 17 also correlated with lack of ganglionic differentiation. Five tumors showed predominNo neuroblastomas were seen in mice heterozygous for antly ganglionic differentiation, and all showed gain of chromosome 17. Two tumors were intermediate in differentiation, and showed no abnormalities of chromochromosome 17. Six tumors were predominantly poorly differentiated, and only one of these showed gain on some 17. since amplification is alleged not to occur in normal
mammalian cells (Tlsty, 1990; Wright et al., 1990) .
Thus, it is probable that early events in the genesis of destabilization of the genome which is a likely prerequisite for MYCN amplification, while maintaining a requirement for other genetic events that contribute to neuroblastic whereas others occur later (Kinzler and Vogelstein, 1996) . Must the multiple mutations culminating in malignancy transformation.
For some human tumors, one or more genetic lesions occur in a particular order?
The data presented here demonstrate that overexpression of MYCN, although typically occur early during the course of tumorigenesis, unlikely to be the initial event in the genesis of human region of chromosome 17 which showed gain was 17q21.3-qter (Plantaz et al., 1997) . In the data presented here, the neuroblastoma, can in fact initiate the sequence of events five tumors showing gain of mouse chromosome 11 shared that lead to neuroblastoma in mice.
an area defined by the much smaller region between bands B2 and B3. Much of this mouse interval is syntenic with Additional genetic lesions contribute to the short arm of human chromosome 17, and only a tumorigenesis very limited region is syntenic with 17q21.3-ter (Mouse The prolonged latent period for tumor formation and the Genome Database, 1996). The region of chromosome 11 additional chromosomal lesions seen by CGH both argue gained in mouse tumors potentially provides a better that tumor formation in the mouse, as in humans, requires definition of the interval gained in human neuroblastoma. genetic lesions in addition to overexpression of MYCN.
Experiments to better characterize this region by fluoresFive mice homozygous for the MYCN transgene had no cence in situ hybridization are in progress. chromosomal gains or losses seen by CGH, suggesting It is intriguing that the chromosomal regions most that neuroblasts with increased MYCN gene dosage may commonly affected in this mouse tumor sample are all require fewer additional genetic events for transformation syntenic to those affected in human tumors. These data than those with lower levels of MYCN. Three of 16 mice suggest that the genetic pathways contributing to mouse hemizygous for the MYCN transgene also showed no neuroblastoma are similar to those observed in the chromosomal copy number abnormalities. This number is human disease. comparable with 4/29 human neuroblastomas examined
In an effort to identify specific genetic lesions that by CGH which also showed no abnormalities (Plantaz might contribute to the genesis of neuroblastoma in the et al., 1997). It has been suggested that the amplicon transgenic mice, we explored the effects of deficiencies carrying MCYN in neuroblastomas may contain other in the tumor suppressor genes NF1, RB1 and p53. We genes that also contribute to tumorigenesis (Manohar found that heterozygous deficiencies in either NF1 or RB1 et al., 1995) . On the other hand, a survey of amplified augmented tumorigenesis. While we cannot exclude the DNA in human neuroblastomas found that MYCN may be possibility that increased tumorigenesis results from haplothe only genetic element held in common among the insufficiency for NF1 and RB1, we presume that sponamplicons in the various tumors (Reiter and Brodeur, taneous damage inactivated or eliminated the remaining 1996). In the mouse model presented here, we encountered alleles of the genes. In contrast, even homozygous defects one tumor that was trisomic for chromosome 12 (which in p53 had no apparent effect on tumorigenesis. These carries mycn). Otherwise, we found no evidence for results are in at least partial accord with the findings to amplification of endogenous mycn (which could serve as date in human neuroblastoma cell lines, which show an indicator for amplification of linked genes as well).
relatively frequent defects only in NF1 (Johnson et al., In mice hemizygous for the MYCN transgene, the genetic 1993; The et al., 1993) Our results with the transgenic losses that occurred most often were of chromosomes 5 model encourage a more diligent examination of RB1 in (4/16 mice), 9 (3/16 mice), 16 (4/16 mice) and X (4/16 human neuroblastoma. mice). The involved chromosomes are syntenic with Twenty percent of the NF1 hemizygous knock-out mice human chromosomes 4 (lost in 7/29 human neuroblastoma developed phaeochromocytomas of the adrenal gland samples), 11 (lost in 11/29 human tumors), 3 (lost in 8/ (Jacks et al., 1994) . We cannot exclude the possibility 29 human tumors) and X (lost in 10/29 human tumors) that some of the increased tumor penetrance seen in our respectively (Plantaz et al., 1997) . The chromosomal NF1 cross relates to an increase in phaeochromocytomas. region 1p36.1-36.2 may carry a tumor suppressor gene This possibility is unlikely, however, as, in contrast to the involved in the genesis of human neuroblastoma (White study of Jacks et al. (1994) , nearly all of the tumors et al., 1995) . Loss of this region may correlate with in our cross were extra-adrenal. In addition, whereas amplification of MYCN (Fong et al., 1992; Caron et al., phaeochromocytoma is a relatively well differentiated 1993), although this view is controversial (Weith et al., neoplasm, the tumors in our study showed a range of 1989). In contrast, CGH detected loss of the syntenic neuronal differentiation from predominantly ganglionic region of chromosome 4 in only two of the 16 mouse elements to undifferentiated small round blue cell tumors. tumors studied here. We cannot presently account for this Different mouse strains showed differing penetrance apparent discrepancy. It is possible that lesions will be for neuroblastoma. Mice back-crossed once to a 129S/v found when the syntenic region is studied at higher strain had increased penetrance over mice back-crossed resolution. Alternatively, providing an excess of Mycn to C57B6/J, whereas mice back-crossed to an FVB/N early in tumor progression may alter the requirements for strain had a lower penetrance of tumors. In all of these subsequent genetic events.
experiments, mice were not back-crossed extensively, and The genetic gains that occurred most often were of therefore the contribution from genetic background was chromosome 17 (in 6/16 mice) and chromosome 11 (in presumably limited. Nevertheless, the data with FVB/N 5/16 mice). The chromosomes involved are syntenic are particularly striking and suggest that a tumor suppressor with human chromosomes 6 (gained in 10/29 human in this strain may protect mice from MYCN-induced neuroblastoma samples) and 17 (gained in 21/29 human neuroblastoma. These mice are being back-crossed repeattumors) respectively (Plantaz et al., 1997) . Gain of mouse edly to achieve homogeneous genetic backgrounds. chromosome 17 also correlated with ganglionic differentiation in 5/6 tumors showing predominantly ganglionic Increased tumor incidence in mice homozygous differentiation by histology.
for the MYCN transgene In human studies, gain of chromosome 17 was the most
The amounts of Mycn varied from one tumor to another. In some of the present examples, the level of expression commonly found genetic abnormality, and the minimal was low, but it inevitably exceeded that found in normal Materials and methods
tissues. The variable levels of expression may in part
Plasmid construction reflect variations among tumors in the ratio of tumor A pGEM7Zf(ϩ)-based plasmid (Promega, Madison, WI) was constructed cells to stroma. Previous experience has indicated that containing a 4.8 kb fragment of the tyrosine hydroxylase promotor (Banerjee et al., 1992) , the rabbit β-globin intron (O'Hare et al., 1981) , transgenes can be tumorigenic even when expressed in a human MYCN cDNA (Ramsay et al., 1986) and the herpes simplex relatively small amounts, so long as the expression is virus thymidine kinase gene terminator/poly(A) sequence (Cole and abnormal to the tissue in question (Nusse et al., 1984) . It Stacy, 1985) . This construct was cut with NsiI (Figure 1) , purified from is possible that the impact of transgene expression may be low melting agarose gels and diluted to 5 μg/ml for injections.
enhanced by the additional genetic lesions that accumulate during progression.
Transgenic mice
Mice were created by standard methods (Hogan et al., 1994) . Founders By inter-breeding transgenic mice that overexpress were derived from Balb/cϫC57B6/J, FVB/N or C57B6/J (Jackson Labs, MYCN, we generated animals with increased dosage of Bar Harbor, ME). Tail DNA was analyzed by Southern analysis using the transgene. Surprisingly, this small increase in gene the MYCN probe or by PCR using 5Ј primer CTTCATCATCTGAATdosage led to a substantial shortening of and an increased CGCTCAGG and 3Ј primer TCATCCTCCAGGACTGCATGTG within MYCN. penetrance of tumors. This result suggests that a small Brain, tumor and grossly abnormal organs were submitted for pathochange in protein levels may have a dramatic impact on logy in all cases. Eight mice had full microscopic analysis of adrenal, signaling pathways. The mechanism by which doubling brain, heart, lung, cortical bone, bone marrow, liver, kidney, pancreas, the gene dosage leads to increased tumorigenesis remains intestine, skin, spleen, skeletal muscle and gonads.
Mice CGH. In fact, all of the five tumors analyzed displayed NF1 and RB1 knock-out mice (Jacks et al., 1992 (Jacks et al., , 1994 were from no additional gains or losses of chromosomal regions.
Jackson Labs (Bar Harbor, ME). Mice deleted for p53 (Donehower This result suggests that increased gene dosage of MYCN et al., 1992) were from Jeff Arbeit. These mice were screened by PCR does not promote further genomic instability. By analogy using primers for the neomycin resistance gene which marks the disrupted allele (5Ј-GATGGATTGCACGCAGGTTC, 3Ј-CTTGAGTGACAACGwith MYCC, perhaps MYCN overexpression leads to TCGAGC).
transformation by up-regulating CDC25 or other signaling molecules and pushing quiescent cells into the cell cycle Histology, immunohistochemistry and electron microscopy (Galaktionov et al., 1996) Tissues and tumors were fixed in 10% formalin, paraffin embedded, sectioned and stained with hematoxylin and eosin. For immunohistochemistry, 7 μm sections were deparaffinized, hydrated and treated
MYCN and neuroblast transformation
with the appropriate mouse monoclonal antibodies directed against MYCN frequently is amplified in neuroblastoma, but rarely synaptophysin (Boehringer Mannheim, Indianapolis, IN, 1 μg/ml), neuron-specific enolase (Dako, Carpinteria, CA, 3 μg/ml), O13 (Signet, has been implicated in other human malignancies. This
Dedham MA, 1 μg/ml), S100 (Dako, 1 μg/ml) or chromogranin A observation raises the question of whether MYCN is enced by B-and T-cell malignancies in transgenic mice which overexpress MYCN under control of the immunoImmunoblotting globulin heavy chain enhancer (Dildrop et al., 1989;  For Western analyses, tissues and tumors were homogenized in Tris- Rosenbaum et al., 1989) . Similarly, MYCN is the only buffered saline (TBS). SDS and β-mercaptoethanol were added to 2 and proto-oncogene that has to date been implicated in neuro-5% respectively. Lysates were sonicated, boiled, microcentrifuged, and blastoma. This observation suggests that neuroblasts may supernatants loaded on 10% SDS-polyacrylamide gels. Proteins transferred electrophoretically to nitrocellulose membranes were blocked with be especially susceptible to the effects of MYCN. It is TBS containing 0.5% NP-40, 0.1% Tween-20, 5% bovine calf serum notable that overexpression of viral transforming genes and 5% non-fat dry milk (TBSTN). Membranes were incubated with from polyomavirus, papovavirus and adenovirus all cause
Mycn antisera (Boehringer Mannheim, Indianapolis, IN, 1 μg/ml) and neuroblastic tumors in transgenic mice (Small et al., 1986;  treated with a horseradish peroxidase-linked sheep anti-mouse secondary antibody (Amersham, Arlington Heights IL, 1 ng/ml), Bands were Aguzzi et al., 1990; Koike et al., 1990; Skalnik et al., visualized by ECL (Amersham, Arlington Heights, IL). Equal amounts 1991). In contrast, few human proto-oncogenes other than of protein were added as measured by Coomassie staining, and by re-
MYCN have been implicated in neuronal transformation
probing with an antibody for phosphofructokinase. (Iwamoto et al., 1993) .
For immunoprecipitations, equal weights of tissues were homogenized in TBS, and SDS was added to 0.5%. Homogenates were boiled, and 4
We have shown that overexpression of MYCN in the volumes of 1.25ϫ RIPA without SDS were added prior to the centrifugdeveloping neuroectoderm of transgenic mice leads to ation. To obtain adequate amounts of tissue, adrenals were harvested neuroblastoma, and that chromosomal gains and losses in from six littermates and pooled. Other tissues were taken from a single these tumors occur in regions syntenic to those in human mouse. Immunoprecipitation was performed using rabbit polyclonal antiMycn antibody Y2 (Ramsay et al., 1986) followed by Western blotting neuroblastoma. These data suggest that the pathogenesis as above.
of neuroblastoma in the transgenic model resembles that of human tumors. Transgenic mice overexpressing MYCN Radiation may therefore be useful for finding additional genes Newborn mice were irradiated before 3 days of age with 3 Gy from a involved in tumorigenesis, and for developing better cesium source. Transgenic mice and non-transgenic littermates were followed for 10 months for development of tumors.
therapies for children with this malignancy.
Comparative genomic hybridization
Hosoi,G., Hara,J., Okamura,T., Osugi,Y., Ishihara,S., Fukuzawa,M., CGH was performed as described previously (Mohapatra et al., 1995) . Okada,A., Okada,S. and Tawa,A. (1994) 359, 295-300. Digital images of red, green and blue fluorochromes were acquired Jacks,T., Shih,T.S., Schmitt,E.M., Bronson,R.T., Bernards,A. and using a Quantitative Image Processing System, and ratio profiles of Weinberg,R.A. (1994) Tumor predisposition in mice heterozygous for fluorescence intensity along chromosomes were quantitated (Piper et al., a targeted mutation in Nf1. Nature Genet., 7, 353-361. 1995) . At least six metaphase chromosomes were analyzed and averaged Johnson,M.R., Look,A.T., DeClue,J.E., Valentine,M.B. and Lowy,D.R. to obtain CGH ratio profiles. Profiles were normalized to an average (1993) Inactivation of the NF1 gene in human melanoma and value of 1.0 for the entire genome, and regions where the green:red neuroblastoma cell lines without impaired regulation of GTP·Ras. ratio deviated significantly from the average were scored as increases or 
